Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.65% to $604.62 Wednesday, on what proved to be an all-around dismal ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

Regeneron (REGN) to acquire 23andMe for $256 million, plans to maintain consumer services and uphold privacy policies. Deal ...

Currently, Regeneron Pharmaceuticals has a market capitalization of $64.44 billion. Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $2,139.25 ...

Regeneron bids for 23andMe for a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's ...

This was the stock's second consecutive day of losses.